TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05032339

Intervention type: DIAGNOSTIC_TEST
Intervention: IUO Plasma Cell Disorders Panel
Description: This Investigational Panel , comprised of 2 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of plasma cell populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having, plasma cell disorders.
Study: NCT05222386

Intervention type: OTHER
Group type: OTHER
Intervention: Parkinson Disease Standard Care
Description: Under usual care, community providers will deliver their usual care and center coordinators will collect data on our outcomes every 3 months. After one year of baseline data collection, eight practices will be randomized to the intervention, which will include clinician training and coaching as well as access to online services for their patients. Per the stepped-wedge design an additional eight practices will be randomized 18 months into the data collection period, and the final eight will enter the intervention 24 months into the data collection period to allow for 12 months intervention recruitment for all practices.
Study: NCT05512299

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Magnetic Stimulation
Description: The CBI is recorded with two different TMS coils. The figure-of-eight coil (2X90 mm) is used for the motor cortex stimulation and the double cone coil (2X126 mm) is used for the cerebellar stimulation. The target recording muscle is first dorsal interosseous (FDI). The TMS intensity used to induce an average MEP amplitude of 0.5 mV is also determined. CBI is measured by a paired TMS with an inter-stimulus interval of 6 ms. That is, the test TMS at M1 is delivered 6 ms following the conditional TMS at contralateral cerebellum.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Magnetic Stimulation
Description: The CBI is recorded with two different TMS coils. The figure-of-eight coil (2X90 mm) is used for the motor cortex stimulation and the double cone coil (2X126 mm) is used for the cerebellar stimulation. The target recording muscle is first dorsal interosseous (FDI). The TMS intensity used to induce an average MEP amplitude of 0.5 mV is also determined. CBI is measured by a paired TMS with an inter-stimulus interval of 6 ms. That is, the test TMS at M1 is delivered 6 ms following the conditional TMS at contralateral cerebellum.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Magnetic Stimulation
Description: The CBI is recorded with two different TMS coils. The figure-of-eight coil (2X90 mm) is used for the motor cortex stimulation and the double cone coil (2X126 mm) is used for the cerebellar stimulation. The target recording muscle is first dorsal interosseous (FDI). The TMS intensity used to induce an average MEP amplitude of 0.5 mV is also determined. CBI is measured by a paired TMS with an inter-stimulus interval of 6 ms. That is, the test TMS at M1 is delivered 6 ms following the conditional TMS at contralateral cerebellum.
Study: NCT05222386

Intervention type: OTHER
Group type: OTHER
Intervention: Online Community-Supported Palliative Care
Description: Neurologist Teleconferences: Training and coaching in palliative care will be provided using the Extension for Community Healthcare Outcomes (ECHO) model augmented by a Community of Inquiry Framework to address a desire for greater peer connection, enhance self-efficacy, and to address potential weaknesses in the ECHO model for more complex interventions such as palliative care.~Additional support services provided to carepartners and patients will be through the Family Caregiver Alliance's CareNav platform, including tailored educational materials, support groups and social support.
Study: NCT05861141

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Selected physical therapy program
Description: Patients will receive a selected physical therapy program for 1 hr, 3 times per week, for 3 successive months in the form of:~* Balance and postural control exercises for 15 minutes, including the following:~  * Standing on balance board.~ * Stoop and recovery.~* Gait training for 45 minutes, including the following:~  * Forward, backward, and sideways walking.~ * Walking with obstacles using wedges and rolls with different diameters and heights.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Patients will receive the same selected physical therapy program as the control group for 15 minutes in addition to treadmill training for 45 minutes, 3 times per week, for 3 successive months.~Treadmill training: Will be practiced according to the following stages:~A- Warm up: 5 minutes.~B- The exercise phase: 35 minutes (three-minute stages), the speed will be increased gradually every 3 minutes intervals until the child no longer be able to walk at the current stage.~C- Cool down: 5 minutes.
Study: NCT06035627

Intervention type: OTHER
Intervention: Prevention hypothermia
Description: Hypothermia was prevented by warming the case group. control group remained stable. As a result, the presence of surgical site infection was followed.
Study: NCT04898673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP1110
Description: Sound Processor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP1110
Description: Sound Processor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP1000
Description: Sound Processor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP1000
Description: Sound Processor
Study: NCT05584072

Intervention type: DIAGNOSTIC_TEST
Intervention: Active pedal plantarflexion (APP) test
Description: Active pedal plantarflexion (APP) test
Study: NCT04316676

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET-MPI Protocol
Description: Patients with suspected CAD who are referred to a clinical PET-MPI will undergo the standard clinical protocol applied in the Emory Nuclear Medicine department.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT-MPI
Description: For the CT-MPI, dynamic volume CT myocardial perfusion applying the dynamic shuttle mode will be used to rapidly cover the entire cardiac anatomy during infusion of a contrast medium bolus for monitoring bolus passage through the left ventricular myocardium. The dynamic shuttle mode consists of an image acquisition during rapid, yet smooth back-and-forth movement of the CT scanner table, so that contrast media bolus passage can be evaluated within the entire left ventricle in a time-resolved fashion. This scan acquisition will be performed during pharmacologically induced stress and during rest conditions. CT-MPI studies will be contrast medium enhanced by 50-70 ml of iodinated contrast agent, administered at a flow rate of 5 mL/s.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT-FFR
Description: Coronary CT angiography (CCTA) will be performed for delineation of the coronary arteries, detection of potential coronary stenosis and FFR calculation. CCTA will be performed at rest following administration of intravenous contrast agent (50-70 mL of iodinated contrast material at a flow rate of 4-5 mL/s). A total radiation dose of approximately 8 millisievert (mSv) has expected to be administered with the stress/rest protocol to the patient. The total amount of contrast agent will not exceed 140 ml.

Intervention type: DRUG
Group type: OTHER
Intervention: Regadenoson
Description: Pharmacological stress testing for the CT-MPI scan will be performed with a single injection of 0.4 mg of regadenoson (Lexiscan).
Study: NCT05772013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Pill
Description: Participants will take azithromycin according to their standard of care prescription.~If the participant is on the seasonal azithromycin treatment arm, they will only take azithromycin during the winter months (October-March) followed by matched placebo (April-September).

Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin Pill
Description: Participants will take azithromycin according to their standard of care prescription.~If the participant is on the seasonal azithromycin treatment arm, they will only take azithromycin during the winter months (October-March) followed by matched placebo (April-September).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo tablets will be matched in appearance, taste and smell to the azithromycin tablets.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: The placebo tablets will be matched in appearance, taste and smell to the azithromycin tablets.
Study: NCT05385250

Intervention type: OTHER
Group type: OTHER
Intervention: Bone sparring radiotherapy
Description: Observation of late side effects from the pelvic bones after bone-sparring radiotherapy for anal cancer
Study: NCT06409364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: small white tablet containing 100mcg of fludrocortsone
Study: NCT05078853

Intervention type: DEVICE
Intervention: Point of care assay for thyroglobulin (POC-Tg) evaluation of a suspected cervical lymph node
Description: FNA Clinic: When a bloody material is seen in the needle, 100 µL of 0.9% saline is drawn via the needle into the syringe. The aspirate is then transferred into an Eppendorf tube. 40 µL is aspirated from the Eppendorf tube and dripped into the middle of the sample well of the POC-Tg kit. Two drops of the buffer are then dispensed into the middle of the sample well. The result of the POC-Tg is obtained and documented after 10 minutes. To compare the accuracy of the POC-Tg kit to the formal immunoassay for Tg, 0.9% saline is added to the aspirate that was left in the Eppendorf tube to a final volume of 0.6 mL. This volume is transferred into a gel containing tube and sent to the clinical laboratory that performs Tg measurement.~Operating room: When an indeterminate or suspicious LN is found, the LN is dissected and evaluated by both the formal evaluation and the POC-Tg. Following dissection of the LN, the ex-vivo POC-Tg is conducted as described above.
Study: NCT06419023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: supervised physical activity intervention using the Pilates Method (exercises on the mat)
Description: Each Pilates session was consisted of: a) introduction to the goal of training, familiarizing new skills (2-3 min); b) Pre-Pilates warm-up and respiratory exercises (5-10 min); c) mat Pilates exercises with the traditional Pilates repertoire: basic, beginner (40 min); d) cool down and endings exercises (5 min); e) session summary (2-3min). When required, exercises were adapted for breast cancer body needs and restrictions. Depending on the purpose of the exercise, different equipment was used (Pilates small ball 22 cm, Swiss ball, small massage balls, resistance band, towels, rollers, boxes, Magic Circle).
Study: NCT06220708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dance movement therapy
Description: Our DMT program was adapted from an integrated somatic dance and visual arts program previously applied to the older population (Hsu, 2023). The intervention was scheduled in the afternoon and lasted for approximately 2 h. As previously recommended, rhythmic and contralateral movements on both sides of the body were emphasized in this study to enhance coordination and stimulation between the left and right cerebral hemispheres (Phillips-Silver and Trainor, 2007). The experimental groups were then subdivided into six groups. Balloons half-filled with water were used as the game in this study to guide individual and grouping rhythms and movements. Additionally, painting was incorporated to help participants understand their bodies and psychological states (Tjasink et al., 2023). Finally, group discussions and mutual support, along with verbal sharing after the DMT exercise, were encouraged.

Intervention type: OTHER
Group type: OTHER
Intervention: yoga training
Description: The yoga program included breathing exercises, Asanas, eye focus, body lock, and meditation. Participants were instructed to adjust their positioning based on their skill level to mitigate the risk of injury. The yoga intervention was scheduled at 2 pm and lasted for approximately 2 h.
Study: NCT05792228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nurse-led standardized intervention
Description: Once the patient in the intervention group decided to undergo cisplatin-based chemotherapy, the nurses would assess the risk factors associated with chemotherapy-induced nausea and vomiting (CINV) and reported to the physicians. During the chemotherapy, nurses would provide education on prevention and control of CINV using web-based approaches. All patients received standard antiemetic regimen, which included Aprepitant, 5-Hydroxytryptamine3-receptor antagonists, and Dexamethasone. If the physician's prescription was not accordance with the standard antiemetic regimen, nurse would remind the physician to adjust the prescription. Patients were recommended to eat small and frequent meals slowly. Overly spicy, fatty, and sweet foods should be avoided. Music relaxation therapy was performed for 60 min each time, once a day, and 3 times in the whole chemotherapy cycle. Follow-up was delivered until the 5th day after chemotherapy.
Study: NCT05450471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid Topical
Description: The L-lactide and trimethynele carbonate (TCM) Terpolymers polymer implant will be placed in the ethmoidal region, at the same time that the nasal endoscopic examination will be performed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04853342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Furmonertinib 80 mg
Description: The initial dose of Furmonertinib 80 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Furmonertinib 80 mg placebo
Description: The initial dose of Furmonertinib 80 mg once daily
Study: NCT06427018

Intervention type: OTHER
Intervention: No intervention.
Description: Observational study with no intervention.

Intervention type: OTHER
Intervention: No intervention.
Description: Observational study with no intervention.
Study: NCT01037387

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Current treatment according to the ATS/ERS guidelines

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIMV group
Description: Current treatment according to the ATS/ERS guidelines and nocturnal BiPAP (IPAP 10-20 cmH2O,EPAP 4-6 cmH2O).
Study: NCT04680689

Intervention type: DIAGNOSTIC_TEST
Intervention: 128 Multislice CT coronary angiography
Description: 128 Multislice CT coronary angiography with the evaluation of coronary stenosis, the plaque vulnerability markers ( necrotic core, low attenuation plaque, spotty calcifications, napkin ring sign, positive remodeling), asses polar maps of the myocardium

Intervention type: DIAGNOSTIC_TEST
Intervention: 128 Multislice CT coronary angiography
Description: 128 Multislice CT coronary angiography with the evaluation of coronary stenosis, the plaque vulnerability markers ( necrotic core, low attenuation plaque, spotty calcifications, napkin ring sign, positive remodeling), asses polar maps of the myocardium

Intervention type: DIAGNOSTIC_TEST
Intervention: 2D Cardiac Transthoracic Echocardiography
Description: 2D Cardiac Transthoracic Echocardiography with the evaluation of the cardiac cavity dimensions

Intervention type: DIAGNOSTIC_TEST
Intervention: 2D Cardiac Transthoracic Echocardiography
Description: 2D Cardiac Transthoracic Echocardiography with the evaluation of the cardiac cavity dimensions

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory Blood tests
Description: Laboratory tests for evaluations the level of inflammatory biomarkers ( hs-CRP, MMP, IL6 and NT-pro-BNP), complete blood count, biochemestry

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory Blood tests
Description: Laboratory tests for evaluations the level of inflammatory biomarkers ( hs-CRP, MMP, IL6 and NT-pro-BNP), complete blood count, biochemestry
Study: NCT06233487

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Repeat hip ultrasound measurements
Description: See earlier
Study: NCT05719805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten
Description: Specified dose on specified days
Study: NCT04927390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil 500mg
Description: Mycophenolate Mofetil oral tablet twice daily for up to 96 weeks
Study: NCT05294250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8
Description: XC8 10 mg film-coated tablets, 3 discrete doses of 20 mg each separated by 7-day wash-out periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8
Description: XC8 10 mg film-coated tablets, 3 discrete doses of 20 mg each separated by 7-day wash-out periods
Study: NCT04967729

Intervention type: DEVICE
Group type: OTHER
Intervention: Device: Butterfly iQ
Description: The Butterfly iQ is an ultrasound system that enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients. It is a non-invasive device and does not impose any health hazards.
Study: NCT05584111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STC-15
Description: STC-15 oral capsules various dosing regimen in 3-week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STC-15
Description: STC-15 oral capsules various dosing regimen in 3-week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STC-15
Description: STC-15 oral capsules various dosing regimen in 3-week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STC-15
Description: STC-15 oral capsules various dosing regimen in 3-week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STC-15
Description: STC-15 oral capsules various dosing regimen in 3-week cycles
Study: NCT05373199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Euglycemic clamp with BC Combo THDB0207
Description: Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Euglycemic clamp with Lantus®
Description: Administration of a single dose of Lantus® during an euglycemic clamp procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Euglycemic clamp with Humalog®
Description: Administration of a single dose of Humalog® during an euglycemic clamp procedure.
Study: NCT04997863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sericin hydrogel sheet impregnated with EBN extract
Description: Sericin hydrogel sheet impregnated with EBN extract will be used as a primary dressing for preventing scar development at one-half of the STSG donor site. Then, the donor site will be covered with adhesive tape (secondary dressing). The application of primary and secondary dressings will be done once daily after shower in the morning or evening. Both dressings will be recommended to wear over the donor site for 8-12 hours per day. Patients will be advised to remove both dressings before shower to clean the donor site and the surrounding skin, and then replace them with new wound dressing sheets in the next day. The duration of the dressing application will be 6 months.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo hydrogel sheet
Description: Placebo hydrogel sheet will be used as a primary dressing for preventing scar development at another half of the STSG donor site. Then, the donor site will be covered with adhesive tape (secondary dressing). The application of primary and secondary dressings will be done once daily after shower in the morning or evening. Both dressings will be recommended to wear over the donor site for 8-12 hours per day. Patients will be advised to remove both dressings before shower to clean the donor site and the surrounding skin, and then replace them with new wound dressing sheets in the next day. The duration of the dressing application will be 6 months.
Study: NCT06259097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 25 mcg vaginally every 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitocin
Description: 3-6 mL intravenously every hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitocin
Description: 3-6 mL intravenously every hour
Study: NCT05856851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: See arm/group descriptions.
Study: NCT06277765

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: IL-4Rα monoclonal antibody

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study: NCT05346809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab in IV form 10 mg/kg doses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Procedures
Description: Standard procedures (standard of care) for transplant
Study: NCT05497492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: single administration of propofol
Study: NCT06409364

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo tablet,
Study: NCT04628988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90011
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Tablet
Study: NCT05497492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol and sufentanil
Description: administration of propofol and sufentanil in combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol and esketamine
Description: administration of propofol and esketamine in combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol and lidocaine
Description: administration of propofol and lidocaine in combination
Study: NCT05709639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized counselling in nutrition
Description: Individualized counselling in nutrition - collaborate on a nutrition plan
Study: NCT05876338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRCaSSM
Description: The intervention group will receive face-to-face training, giving patient education booklet and telephone counseling based on the symptom management model. After the training, it is planned to provide telephone counseling for a total of 6 times, once every 2 weeks for 3 months.
Study: NCT05571020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mat pilates
Description: Both groups adapted for their rides by not participating in a different exercise and meal. In the study, they were not found in any store in the control groups. In the Mat-Pates Group, information about the 5 key elements of the study and pilates team, perspective (-neck-shoulder-waist-abdominal placement), lumbopel stabilization, scapular stabilization, review and information was covered. Then, in the study groups, it was purchased from groups of 5-6 people at most for one hour a day. In order to participate in all these application activities, he continues his life without participating in any evaluation.